GSK Granted Breakthrough Therapy Designation for Cancer Drug

Jan 13, 2014

GSK

The FDA has granted Breakthrough Therapy designation for GlaxoSmithKline's Tafinlar (dabrafenib) for treatment of patients with lung cancer.

Tafinlar, already approved for melanoma, was designated an FDA breakthrough therapy on Monday for for treatment of patients with metastatic BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) who have received at least one prior line of platinum-containing chemotherapy.

Enacted as part of the 2012 FDA Safety and Innovation Act, the Breakthrough Therapy designation is intended to expedite development and review of drugs to treat serious or life-threatening medical conditions when preliminary clinical evidence demonstrates that the drug may have substantial improvement on at least one clinically significant endpoint over available therapies.

 

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments